Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer.

ABSTRACT:

Objectives

This phase I study aimed to evaluate the antitumor effect and safety of programmed death-ligand-1 (PD-L1)-targeting autologous chimeric antigen receptor T (CAR-T) cells for patients with non-small cell lung cancer (NSCLC).

Methods

Programmed death-ligand-1-specific CAR-T cells were generated using lentiviral transduction. Four patients with NSCLC were recruited, but only one patient was finally involved. CAR-T cells were infused on three different days (total dose during therapy, 1 × 10⁶ CAR-T cells kg^-1 body weight). The date on which the patient received the first CAR-T cell infusion was designated as Day 0.

Results

Circulating CAR-T cells accounted for 3.30% of the patient's peripheral blood T cells detected by FACS analysis during

SUBMITTER: Liu H 

PROVIDER: S-EPMC7546952 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature